Spermidine as a New Therapy for Colitis and Chemopreventive for Colitis-associated Carcinogenesis

亚精胺作为结肠炎的新疗法和结肠炎相关癌的化学预防

基本信息

  • 批准号:
    10180436
  • 负责人:
  • 金额:
    $ 67.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-31 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

SUMMARY: Inflammatory bowel disease (IBD) afflicts over three million people in the USA, is increasing worldwide, and leads to colitis-associated carcinogenesis (CAC). We are seeking new adjunctive IBD therapies that are safe, effective, and inexpensive that could also reduce risk for CAC. Spermidine (Spd) is a polyamine generated from putrescine and from back-conversion of spermine by spermine oxidase (SMOX). Recent high-impact studies have shown that Spd supplementation improves cardiovascular health, longevity and quality of life in aging, and does not increase the risk for cancer. Spd has been used successfully in Phase I clinical trials. We have developed a sensitive, accurate mass spectrometry-based assay for polyamine detection, which has enhanced our capabilities for this project. Our recent discoveries support the use of Spd as a new strategy for colitis treatment and CAC prevention. The long-term goal is to further elucidate the scope and mechanisms underlying the protective effect of Spd to gain insights needed for future human clinical trials in IBD. Our proposed studies are supported by our data indicating that: 1) Expression of SMOX, a key source of Spd, is reduced in patients with ulcerative colitis (UC) and associated dysplasia. 2) Mice with Smox deletion have reduced Spd in the colon and exacerbation of both dextran sulfate sodium (DSS) colitis, a model with features of UC, and CAC in the azoxymethane (AOM)-DSS model. 3) Spd supplementation restores colon Spd levels and protects against colitis and CAC. 4) Spd is the substrate for generation of hypusine, an amino acid produced by deoxyhypusine synthase (DHPS), which is required for a highly specific form of protein translation, hypusination, involving activation of eukaryotic translation initiation factor 5A (EIF5A) and formation of hypusinated EIF5A (EIF5AHyp). DHPS levels are low in UC patients. EIF5AHyp is reduced by Smox deletion and restored by Spd during DSS colitis and AOM- DSS-induced CAC, regulates macrophage function, and enhances colonic epithelial restitution. 5) Electrophiles, such as levuglandins (LGs), are damaging products of lipid peroxidation that can lead to immune dysfunction and neoplastic risk by forming adducts with proteins and DNA; we found increased adducts in human UC and CAC, and a specific scavenger of electrophiles reduced adduct formation and carcinogenesis in the AOM-DSS model. Importantly, we demonstrate that Spd can scavenge LGs. We hypothesize that potential benefits of Spd in colitis and carcinogenesis are due to effects on immune responses, epithelial function, hypusination, and electrophile scavenging. Our Aims are: 1) To determine the molecular and cellular mechanisms of protection by Spd in acute and chronic colitis models and CAC, including effects on the transcriptome/metabolome, autophagy, and immune cell versus epithelial cell function using transgenic mice with cell-specific human SMOX expression. 2) To determine if Spd acts through hypusination, using mice with epithelial- or myeloid-specific deletion of Dhps. 3) To determine the role of Spd as an electrophile scavenger in reducing inflammation, genomic instability, and tumorigenesis. We expect to deliver a new strategy for colitis treatment in IBD and for CAC prevention.
总结: 炎症性肠病(IBD)困扰着美国超过300万人,在世界范围内正在增加, 导致结肠炎相关致癌作用(CAC)。我们正在寻找新的安全的IBD治疗方法, 有效且廉价,也可以降低CAC的风险。亚精胺(Spd)是一种多胺, 腐胺和来自精胺氧化酶(SMOX)对精胺的反转化。最近的高影响力研究 已经表明,补充亚精胺可以改善心血管健康、长寿和老年生活质量, 不会增加患癌症的风险。Spd已成功用于I期临床试验。我们有 开发了一种灵敏,准确的基于质谱的多胺检测方法,提高了 我们在这个项目上的能力。我们最近的发现支持使用Spd作为结肠炎的新策略 治疗和CAC预防。长期目标是进一步阐明其范围和机制 Spd的保护作用,以获得未来IBD人体临床试验所需的见解。我们建议的研究 我们的数据表明:1)SMOX(Spd的关键来源)的表达在患者中减少 溃疡性结肠炎(UC)和相关的发育不良。2)Smox缺失的小鼠结肠中Spd减少 以及葡聚糖硫酸钠(DSS)结肠炎(一种具有UC特征的模型)和CAC的恶化。 氧化偶氮甲烷(AOM)-DSS模型。3)补充Spd可恢复结肠Spd水平并预防结肠炎 和CAC。4)Spd是生成羟腐胺赖氨酸的底物,羟腐胺赖氨酸是由脱氧羟腐胺赖氨酸合成酶产生的氨基酸 (DHPS),这是一种高度特异性的蛋白质翻译形式所必需的,hypusination,涉及激活 真核生物翻译起始因子5A(EIF 5A)和羟腐胺赖氨酸化的EIF 5A(EIF 5AHyp)的形成。DHPS水平 在UC患者中是低的。EIF 5AHyp在DSS结肠炎和AOM期间通过Smox缺失减少并通过Spd恢复- DSS诱导的CAC,调节巨噬细胞功能,并增强结肠上皮恢复。5)亲电体, 如左甘定(LGs),是脂质过氧化的破坏性产物,可导致免疫功能障碍 与蛋白质和DNA形成加合物和肿瘤风险;我们发现在人类UC中加合物增加, CAC和亲电体的特异性清除剂减少AOM-DSS中的加合物形成和致癌作用 模型重要的是,我们证明了Spd可以抑制LG。我们假设亚精胺的潜在益处 在结肠炎和癌变中的作用是由于对免疫反应、上皮功能、羟腐胺酸作用和 亲电体清除我们的目的是:1)确定保护的分子和细胞机制, Spd在急性和慢性结肠炎模型和CAC中的作用,包括对转录组/代谢组,自噬, 和免疫细胞对上皮细胞功能的研究。 2)为了确定Spd是否通过hypusination起作用,使用具有上皮或骨髓特异性Dhps缺失的小鼠。 3)为了确定Spd作为亲电清除剂在减少炎症、基因组不稳定性和 肿瘤发生我们期望为IBD的结肠炎治疗和CAC预防提供新的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Keith T. Wilson其他文献

Mo1146 - <em>Helicobacter Pylori</em> Genetic Ancestry in Central America is Consistent with Disrupted Co-Evolution, with Implications for Gastric Cancer Risk
  • DOI:
    10.1016/s0016-5085(17)32349-1
  • 发表时间:
    2017-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Gloria Tavera;Ricardo L. Dominguez;Jacquelaine Bartlett;Barbara G. Schneider;Charlotte Buehler Cherry;Dawn Israel;Judith Romero-Gallo;Robertino M. Mera;M. Blanca Piazuelo;Richard M. Peek;Keith T. Wilson;Scott Williams;Douglas Morgan
  • 通讯作者:
    Douglas Morgan
Cyclosporin a (CsA) induces enhanced leukocyte binding by human intestinal microvascular endothelial cells (HIMEC): A mechanism for therapeutic failure in long term IBD therapy?
  • DOI:
    10.1016/s0016-5085(00)85346-9
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Parvaneh Rafiee;Christopher P. Johnson;Pamela J. Fisher;Thomas H. Lamirand;Mona S. Li;Keith T. Wilson;David G. Binion
  • 通讯作者:
    David G. Binion
1145 EVALUATION OF THE SAFETY AND EFFICACY OF EFLORNITHINE (DIFLUOROMETHYLORNITHINE, DFMO) IN PATIENTS WITH GASTRIC PREMALIGNANT CONDITIONS IN THE HIGH INCIDENCE AREAS OF LATIN AMERICA
  • DOI:
    10.1016/s0016-5085(24)01098-9
  • 发表时间:
    2024-05-18
  • 期刊:
  • 影响因子:
  • 作者:
    Douglas R. Morgan;Ricardo L. Dominguez;Dalton A. Norwood;Eleazar E. Montalvan-Sanchez;Maria B. Piazuelo;Jessica Hernandez-Marrero;Maria Gonzalez-Pons;Elizabeth Bruckheimer;Mark Beasley;Marcia R. Cruz-Correa;Keith T. Wilson
  • 通讯作者:
    Keith T. Wilson
125 - Geospatial Analyses Identify a Clustering of Diffuse Gastric Cancers and Related Risk Exposures in Central America
  • DOI:
    10.1016/s0016-5085(17)30481-x
  • 发表时间:
    2017-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Charlotte Buehler Cherry;Veronica Escamilla;Ricardo L. Dominguez;Barbara G. Schneider;Margaret L. Gulley;Gloria Tavera;Scott Williams;Dawn Israel;M. Blanca Piazuelo;Keith T. Wilson;Richard M. Peek;Michael Emch;Douglas Morgan
  • 通讯作者:
    Douglas Morgan
1077 - <em>Helicobacter Pylori Cag</em><sup>+</sup> Strains Induce Alterations in the <em>In Vivo</em> Epithelial Proteome that are Associated with Progression of Gastric Carcinogenesis
  • DOI:
    10.1016/s0016-5085(18)31092-8
  • 发表时间:
    2018-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jennifer M. Noto;Kristie Lindsey-Rose;Amanda Hachey;Alberto G. Delgado;Judith Romero-Gallo;Barbara G. Schneider;Timothy Cover;Keith T. Wilson;Juan Carlos Roa;M. Blanca Piazuelo;Richard M. Peek
  • 通讯作者:
    Richard M. Peek

Keith T. Wilson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Keith T. Wilson', 18)}}的其他基金

BCCMA: Targeting Gut-Microbiome in Veterans Deployment Related Gastrointestinal and Liver Diseases: Dysbiosis, PTSD, and Epithelial and Immune Biology in Inflammatory Bowel Disease in Veterans
BCCMA:针对退伍军人部署相关胃肠道和肝脏疾病的肠道微生物组:退伍军人炎症性肠病中的生态失调、创伤后应激障碍以及上皮和免疫生物学
  • 批准号:
    10586940
  • 财政年份:
    2023
  • 资助金额:
    $ 67.54万
  • 项目类别:
Spermidine as a New Therapy for Colitis and Chemopreventive for Colitis-associated Carcinogenesis
亚精胺作为结肠炎的新疗法和结肠炎相关癌的化学预防
  • 批准号:
    10379376
  • 财政年份:
    2021
  • 资助金额:
    $ 67.54万
  • 项目类别:
Spermidine as a New Therapy for Colitis and Chemopreventive for Colitis-associated Carcinogenesis
亚精胺作为结肠炎的新疗法和结肠炎相关癌的化学预防
  • 批准号:
    10579252
  • 财政年份:
    2021
  • 资助金额:
    $ 67.54万
  • 项目类别:
Dysregulated Polyamine Metabolism in H. pylori-associated Gastric Inflammation and Disease Progression
幽门螺杆菌相关胃炎症和疾病进展中多胺代谢失调
  • 批准号:
    10196972
  • 财政年份:
    2020
  • 资助金额:
    $ 67.54万
  • 项目类别:
Dysregulated Polyamine Metabolism in H. pylori-associated Gastric Inflammation and Disease Progression
幽门螺杆菌相关胃炎症和疾病进展中多胺代谢失调
  • 批准号:
    10620757
  • 财政年份:
    2020
  • 资助金额:
    $ 67.54万
  • 项目类别:
Dysregulated Polyamine Metabolism in H. pylori-associated Gastric Inflammation and Disease Progression
幽门螺杆菌相关胃炎症和疾病进展中多胺代谢失调
  • 批准号:
    10572035
  • 财政年份:
    2020
  • 资助金额:
    $ 67.54万
  • 项目类别:
2019 Polyamines GRS/GRC
2019 多胺 GRS/GRC
  • 批准号:
    9750998
  • 财政年份:
    2019
  • 资助金额:
    $ 67.54万
  • 项目类别:
Immunomodulatory effects of arginine supplementation in colitis and colon cancer
补充精氨酸对结肠炎和结肠癌的免疫调节作用
  • 批准号:
    8857372
  • 财政年份:
    2013
  • 资助金额:
    $ 67.54万
  • 项目类别:
Immunomodulatory effects of arginine supplementation in colitis and colon cancer
补充精氨酸对结肠炎和结肠癌的免疫调节作用
  • 批准号:
    8690770
  • 财政年份:
    2013
  • 资助金额:
    $ 67.54万
  • 项目类别:
Immunomodulatory effects of arginine supplementation in colitis and colon cancer
补充精氨酸对结肠炎和结肠癌的免疫调节作用
  • 批准号:
    9300834
  • 财政年份:
    2013
  • 资助金额:
    $ 67.54万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.54万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了